-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Brain atrophy is an imaging diagnosis .
Brain atrophy is an imaging diagnosis .
Recent studies have shown that the classification of brain atrophy subtypes through structural MRI, so that it has a typical (ie hippocampus and neocortical associated area), hippocampus reserved area or edge-based atrophy pattern, can identify including Alzheimer's disease (AD) biological and clinically meaningful manifestations.
Classification of brain atrophy subtypes by structural MRI, so that it has typical (ie hippocampus and neocortical associated areas), hippocampus reserved areas or marginal atrophy patterns, which can identify organisms including Alzheimer's disease (AD) Academic and clinically meaningful performance.
At the same time, studies have suggested that brain atrophy subtypes are related to different cognitive declines in AD and AD prodromal phase.
Since previous studies were mainly based on pathophysiological assumptions, the samples were limited to patients with amyloid (Aβ)-positive biomarkers, patients with amnestic mild cognitive impairment (MCI), and/or patients with dementia and AD clinical syndromes.
To this end, the MENTOLT study led by experts from the Neurodegenerative Diseases and Neuroscience Research Center of the University of Bordeaux in France gave the answer, and the results were published in the latest Alzheimer' Dementia journal.
During the 4-year follow-up period, a total of 213 cases of dementia occurred, with an incidence rate of 3.
In the entire analysis sample and Aβ-positive participants, typical/diffuse brain atrophy was associated with faster cognitive decline.
The incidence of dementia varies with atrophy subtypes.
According to the type of brain atrophy, the linear mixed model is adjusted according to age, gender, education level and population status to adjust the cognitive changes in 4 years.
According to the type of brain atrophy, the linear mixed model is adjusted according to age, gender, education level and population status to adjust the cognitive changes in 4 years.
Typical/diffuse brain atrophy (HR=4.
It can be seen that the classification of different regional atrophy subtypes is expected to predict different subsequent patterns of cognitive decline in patients and the conversion rate to different causes of dementia.
references:
Planche V, et al.
onlinelibrary.
wiley.
com/doi/10.
1002/alz.
12231" target="_blank" rel="noopener">Clinical relevance of brain atrophy subtypes categorization in memory clinics.
Leave a message here